How effective is cemiplimab?

Cemiplimab is an important immunotherapy drug widely used to treat some types of cancer. Its therapeutic effect has been verified in multiple clinical trials, especially for patients with advanced squamous cell non-small cell lung cancer (SCC). The following is a detailed analysis combined with clinical trial data to evaluate the therapeutic effect of cimepilimab.

Clinical trial data:

1.Advanced squamous cell non-small cell lung cancer (SCC):

Clinical trial name:EMPOWER-Lung 1.

Trial Design: This is a Phase III clinical trial designed to evaluate the efficacy of cimepilimab in the treatment of patients with advanced non-small cell lung cancer. The trial included 1,041 patients, some of whom received cimepilimab and others who received chemotherapy.

Results: Trial results showed that patients treated with cimepilimab showed a significant improvement in overall survival, with some patients living several months longer. This result is particularly important for patients who have already received chemotherapy or are not sensitive to chemotherapy, as it provides an effective treatment option.

Additional measures: In addition, cimepilimab significantly reduced the risk of disease progression and improved quality of life. Patients often tolerate immunotherapy better because it has fewer side effects.

2.Squamous cell carcinoma of the skin (SCC):

Clinical trial name:EMPOWER-Skin 1.

Trial Design: This is a Phase II clinical trial evaluating the efficacy of cimepilimab in patients with a specific type of cutaneous squamous cell carcinoma (SCC). The trial included 28 patients, all with advanced or recurrent SCC.

Results: The trial results show that cimepilimab has significant efficacy in treating skinSCC. Some patients experience tumor shrinkage or even complete tumor disappearance. This is an important breakthrough for patients who have failed traditional treatments.

3.Effective mechanism:

The therapeutic mechanism of cimepilimab is closely related to its mechanism of action. It restores the immune system's aggressiveness against cancer by blocking the interaction of the PD-1 (programmed death -1) receptor with PD-L1 (programmed death ligand 1). PD-1 and PD-L1 are immune checkpoint molecules that help maintain the balance of the immune system under normal circumstances, but in some cancers, they are abused to suppress the immune system's response, thereby helping cancer cells escape immune attack. Cimepilimab works by lifting this inhibition and activating TT cells so that they can more effectively recognize, attack and eliminate cancer cells.

Cimepilimab is an immunotherapy drug that has shown significant efficacy in clinical trials, particularly in patients with advanced non-small cell lung cancer (SCC) and certain types of skin SCC. It extends patient survival, reduces the risk of disease progression, and improves quality of life. This achievement provides new treatment options for patients for whom traditional treatments are ineffective or unsuitable. However, the effectiveness of treatment may vary among individuals, so patients should receive treatment under the supervision of a physician to determine the best treatment option. With further research and clinical practice, cimepilimab is expected to continue to improve the outlook for cancer treatment.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.